长期缬更昔洛韦治疗提升胶质母细胞瘤慢病毒自杀基因疗法效果
该研究在胶质母细胞瘤异种移植模型中,比较了短期更昔洛韦与长期缬更昔洛韦对HSV-TK自杀基因疗法的效果。结果显示复发肿瘤的TK阳性细胞体外仍对更昔洛韦敏感,而长期缬更昔洛韦治疗相比短期更昔洛韦显著延长生存期。复发肿瘤更具侵袭性、血管生成减少且EGFR表达上调,但联合厄洛替尼未增强疗效。
要点
- 复发肿瘤中TK阳性细胞体外仍对更昔洛韦敏感。
- 长期缬更昔洛韦(3个月)较短期更昔洛韦(3周)显著延长生存期。
- 复发肿瘤侵袭性增加、血管生成减少且EGFR表达上调。
核心结论
- 在HSV-TK介导的自杀基因疗法临床试验中,应考虑用长期缬更昔洛韦治疗替代短期更昔洛韦治疗。
研究设计与样本
- 研究从自杀基因治疗后复发的异种移植肿瘤中分选TK-GFP阳性胶质瘤细胞,体外检测其对更昔洛韦的敏感性。
- 胶质母细胞瘤异种移植模型分别接受HSV-TK/更昔洛韦、HSV-TK/缬更昔洛韦或HSV-TK/缬更昔洛韦联合厄洛替尼治疗,通过MRI分析肿瘤生长并评估生存及形态分子变化。
主要发现
- 复发异种移植肿瘤的TK-GFP阳性细胞体外仍保持对更昔洛韦的敏感性。
- 长期(3个月)缬更昔洛韦给药相比短期(3周)更昔洛韦应用产生显著生存优势。
- 治疗组复发肿瘤较原发肿瘤更具侵袭性、血管生成减少,且EGFR表达显著上调。
- 厄洛替尼联合治疗未增加疗效。
临床怎么用
- 在HSV-TK自杀基因疗法临床试验中,可考虑采用长期缬更昔洛韦给药方案替代短期更昔洛韦。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suicide gene therapy for malignant gliomas has shown encouraging results in the latest clinical trials. However, prodrug application was most often restricted to short-term treatment (14 days), especially when replication-defective vectors were used. We previously showed that a substantial fraction of herpes simplex virus thymidine kinase (HSV-TK) transduced tumor cells survive ganciclovir (GCV) treatment in an orthotopic glioblastoma (GBM) xenograft model. Here we analyzed whether these TK+ tumor cells are still sensitive to prodrug treatment and whether prolonged prodrug treatment can enhance treatment efficacy. METHODS: Glioma cells positive for TK and green fluorescent protein (GFP) were sorted from xenograft tumors recurring after suicide gene therapy, and their sensitivity to GCV was tested in vitro. GBM xenografts were treated with HSV-TK/GCV, HSV-TK/valganciclovir (valGCV), or HSV-TK/valGCV + erlotinib. Tumor growth was analyzed by MRI, and survival as well as morphological and molecular changes were assessed. RESULTS: TK-GFP+ tumor cells from recurrent xenograft tumors retained sensitivity to GCV in vitro. Importantly, a prolonged period (3 mo) of prodrug administration with valganciclovir (valGCV) resulted in a significant survival advantage compared with short-term (3 wk) application of GCV. Recurrent tumors from the treatment groups were more invasive and less angiogenic compared with primary tumors and showed significant upregulation of epidermal growth factor receptor (EGFR) expression. However, double treatment with the EGFR inhibitor erlotinib did not increase therapeutic efficacy. CONCLUSION: Long-term treatment with valGCV should be considered as a replacement for short-term treatment with GCV in clinical trials of HSV-TK mediated suicide gene therapy.
引用
- Hossain JA, Latif MA, Ystaas LAR, et al. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma. Neuro Oncol. 2019. PMID: 30958558. doi:10.1093/neuonc/noz060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。